Sarepta slumps as gene therapy setback adds to drug pipeline woes – Reuters

Written by

admin

in

  1. Sarepta slumps as gene therapy setback adds to drug pipeline woes  Reuters
  2. Sarepta Therapeutics Stock Is Tumbling After The Close: Here’s Why  Benzinga
  3. Sarepta’s Duchenne gene therapy misses main goal in late-stage study; shares fall  Yahoo Finance
  4. Sarepta Therapeutics Inc reports results for the quarter ended September 30 – Earnings Summary  TradingView
  5. Sarepta’s Duchenne confirmatory trial fails, but biotech will ask FDA for full approval anyways  Endpoints News

Continue Reading

More posts